Kellanova (NYSE:K) reported a first-quarter FY24 sales decline of 4.3% year-on-year to $3.20 billion, beating the analyst consensus estimate of $3.16 billion.
While net sales in the first quarter were negatively impacted by adverse currency translation and the 2023 divestiture of its business in Russia, the company’s organic-basis growth remained at the upper end of its long-term target range.
Adjusted EPS of $1.01 beat the consensus estimate of $0.85.
North America’s sales recorded a slight increase, Europe fell 1%, Latin America’s sales gained 11%, and ...